HC Wainwright Weighs in on aTyr Pharma Q1 Earnings

aTyr Pharma, Inc. (NASDAQ:ATYR) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of aTyr Pharma in a research report issued to clients and investors on Friday, March 6th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.15) per share for the quarter. The consensus estimate for aTyr Pharma’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for aTyr Pharma’s Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.19) EPS.

Several other research firms have also issued reports on ATYR. Jefferies Financial Group reissued a “buy” rating on shares of aTyr Pharma in a research report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of aTyr Pharma in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $25.67.

aTyr Pharma Stock Performance

Shares of ATYR stock opened at $0.94 on Monday. The firm’s 50-day simple moving average is $0.85 and its two-hundred day simple moving average is $1.33. aTyr Pharma has a 52 week low of $0.64 and a 52 week high of $7.29. The firm has a market cap of $91.76 million, a price-to-earnings ratio of -1.18 and a beta of 0.55.

aTyr Pharma (NASDAQ:ATYR) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04.

Hedge Funds Weigh In On aTyr Pharma

Large investors have recently made changes to their positions in the business. California State Teachers Retirement System bought a new stake in shares of aTyr Pharma in the 2nd quarter worth approximately $28,000. Ameritas Investment Partners Inc. purchased a new position in aTyr Pharma during the second quarter valued at $45,000. Main Street Financial Solutions LLC boosted its holdings in aTyr Pharma by 7.0% in the second quarter. Main Street Financial Solutions LLC now owns 143,600 shares of the company’s stock worth $728,000 after acquiring an additional 9,350 shares in the last quarter. Legal & General Group Plc bought a new stake in aTyr Pharma in the second quarter worth $49,000. Finally, Raymond James Financial Inc. grew its stake in shares of aTyr Pharma by 79.3% in the second quarter. Raymond James Financial Inc. now owns 24,839 shares of the company’s stock worth $126,000 after acquiring an additional 10,989 shares during the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.